Diligence memo · auto-generated · as of July 2, 2026
inSoma Bio, Inc.
inSoma Bio, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
inSoma Bio, Inc. operates in Biotechnology, based in DURHAM, NC, USA. Helping Plastic Surgeons Rebuild Fat
Sub-sector tags: Synthetic Biology, Medical Devices.
Capital & rounds (filed)filed
inSoma Bio, Inc. has raised $6.9M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.7M on 2023-04-17.
Most recent recorded round closed around 2025-09-24.
Valuation (modeled)modeled
Provath models inSoma Bio, Inc. at approximately $6.6M (range $1.9M–$13M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.44× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era. Within the normal band (144% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 9 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 49% of Biotechnology peers (4293 compared).
Modeled value ranks above 13% of those peers.
Closest niche peers: Carna Inc., NRX Pharmaceuticals, Inc., Vicora, Inc., MH3D, Inc., Oral Genome Corp..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.